UY24286A1 - Nuevo proceso para la producción de una sal ácida calcica amorfa - Google Patents
Nuevo proceso para la producción de una sal ácida calcica amorfaInfo
- Publication number
- UY24286A1 UY24286A1 UY24286A UY24286A UY24286A1 UY 24286 A1 UY24286 A1 UY 24286A1 UY 24286 A UY24286 A UY 24286A UY 24286 A UY24286 A UY 24286A UY 24286 A1 UY24286 A1 UY 24286A1
- Authority
- UY
- Uruguay
- Prior art keywords
- calcica
- production
- solvent
- acid salt
- new process
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 4
- 239000002904 solvent Substances 0.000 abstract 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 229960005370 atorvastatin Drugs 0.000 abstract 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000006260 foam Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000010907 mechanical stirring Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 238000001291 vacuum drying Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US145395P | 1995-07-17 | 1995-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24286A1 true UY24286A1 (es) | 1997-01-17 |
Family
ID=21696097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24286A UY24286A1 (es) | 1995-07-17 | 1996-07-17 | Nuevo proceso para la producción de una sal ácida calcica amorfa |
Country Status (37)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| IN191236B (enExample) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6646133B1 (en) | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
| HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| AU3289102A (en) * | 2000-11-16 | 2002-06-11 | Teva Pharma | Hydrolysis of (R(R*,R*))-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino) carbonyl)-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156280A0 (en) | 2000-12-27 | 2004-01-04 | Ciba Sc Holding Ag | Crystalline forms of atorvastatin |
| WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| IN190564B (enExample) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| MXPA03010266A (es) * | 2001-06-29 | 2004-03-10 | Warner Lambert Co | Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin). |
| US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| EP1572638A4 (en) | 2001-08-31 | 2010-05-05 | Morepen Lab Ltd | IMPROVED METHOD FOR THE PRODUCTION OF AMORPHIC ATORVASTATIN CALCIUM SALT (2: 1) |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
| US7230120B2 (en) | 2002-03-18 | 2007-06-12 | Biocon | Amorphous HMG-CoA reductase inhibitors of desired particle size |
| RU2309141C2 (ru) * | 2002-03-18 | 2007-10-27 | Байокон Лимитид | АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| WO2003099785A1 (en) * | 2002-05-28 | 2003-12-04 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| EP1562583A1 (en) * | 2002-09-03 | 2005-08-17 | Morepen Laboratories Ltd. | Atorvastatin calcium form vi or hydrates thereof |
| EP1615884B1 (en) | 2003-04-11 | 2016-06-29 | LEK Pharmaceuticals d.d. | Process for the preparation of amorphous calcium salt of atorvastatin |
| ATE425132T1 (de) | 2003-04-22 | 2009-03-15 | Biocon Ltd | Neues verfahren zur stereoselektiven reduktion von beta-ketoestern |
| US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| AU2003272080A1 (en) | 2003-09-18 | 2005-04-06 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| WO2005092852A1 (en) | 2004-03-17 | 2005-10-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| CA2649054A1 (en) | 2004-05-05 | 2005-11-10 | Pfizer Products Inc. | Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
| CA2573969C (en) * | 2004-07-16 | 2014-02-04 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| CA2578722C (en) | 2004-08-27 | 2010-02-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
| US20080009540A1 (en) * | 2004-09-30 | 2008-01-10 | Srinivasulu Gudipati | Amorphous Atorvastatin Calcium |
| WO2006045018A1 (en) * | 2004-10-18 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
| CN101048141A (zh) * | 2004-10-28 | 2007-10-03 | 沃尼尔·朗伯有限责任公司 | 形成非晶形的阿托伐他汀的方法 |
| AU2005305460B2 (en) | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| JP2008521878A (ja) * | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 非晶質アトルバスタチンの医薬組成物及びその製造のための方法 |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| WO2007103223A1 (en) * | 2006-03-01 | 2007-09-13 | Teva Pharmaceutical Industries Ltd. | Process for preparing a crystalline form of atorvastatin hemi-calcium |
| WO2008053312A2 (en) * | 2006-11-02 | 2008-05-08 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate |
| US7834195B2 (en) | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
| WO2009007856A2 (en) * | 2007-07-11 | 2009-01-15 | Actavis Group Ptc Ehf | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium |
| US20090124817A1 (en) * | 2007-11-09 | 2009-05-14 | The Industry & Academic Cooperation In Chungnam National University | Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles |
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| WO2010066846A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Method for the isolation of atorvastatin |
| SI2373609T1 (sl) | 2008-12-19 | 2013-12-31 | Krka, D.D., Novo Mesto | Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov |
| EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| CZ294108B6 (cs) | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové |
-
1996
- 1996-07-03 HR HR960312A patent/HRP960312B1/xx not_active IP Right Cessation
- 1996-07-16 PL PL324463A patent/PL191017B1/pl unknown
- 1996-07-16 DK DK96924553T patent/DK0839132T5/da active
- 1996-07-16 AR ARP960103599A patent/AR002849A1/es not_active Application Discontinuation
- 1996-07-16 KR KR10-1998-0700348A patent/KR100400805B1/ko not_active Expired - Lifetime
- 1996-07-16 RO RO98-00060A patent/RO120069B1/ro unknown
- 1996-07-16 AU AU64978/96A patent/AU700794B2/en not_active Expired
- 1996-07-16 AT AT96924553T patent/ATE199542T1/de not_active IP Right Cessation
- 1996-07-16 NZ NZ313008A patent/NZ313008A/xx not_active IP Right Cessation
- 1996-07-16 WO PCT/US1996/011807 patent/WO1997003960A1/en not_active Ceased
- 1996-07-16 SI SI9630284T patent/SI0839132T1/xx unknown
- 1996-07-16 GE GEAP19964149A patent/GEP20002027B/en unknown
- 1996-07-16 PT PT96924553T patent/PT839132E/pt unknown
- 1996-07-16 BR BR9609714A patent/BR9609714A/pt not_active Application Discontinuation
- 1996-07-16 UA UA98020823A patent/UA50743C2/uk unknown
- 1996-07-16 MX MX9708959A patent/MX9708959A/es unknown
- 1996-07-16 EE EE9700369A patent/EE03605B1/xx unknown
- 1996-07-16 EP EP96924553A patent/EP0839132B1/en not_active Revoked
- 1996-07-16 HU HU9903017A patent/HU220343B/hu unknown
- 1996-07-16 IL IL12216196A patent/IL122161A/xx not_active IP Right Cessation
- 1996-07-16 CN CN96195631A patent/CN1087289C/zh not_active Expired - Lifetime
- 1996-07-16 CZ CZ1998122A patent/CZ289421B6/cs not_active IP Right Cessation
- 1996-07-16 ES ES96924553T patent/ES2156997T3/es not_active Expired - Lifetime
- 1996-07-16 EA EA199800128A patent/EA000625B1/ru not_active IP Right Cessation
- 1996-07-16 CA CA002220455A patent/CA2220455C/en not_active Expired - Lifetime
- 1996-07-16 IN IN1579DE1996 patent/IN185276B/en unknown
- 1996-07-16 SK SK58-98A patent/SK283204B6/sk not_active IP Right Cessation
- 1996-07-16 DE DE69611999T patent/DE69611999T2/de not_active Revoked
- 1996-07-16 JP JP50681497A patent/JP4064459B2/ja not_active Expired - Lifetime
- 1996-07-17 ZA ZA9606043A patent/ZA966043B/xx unknown
- 1996-07-17 UY UY24286A patent/UY24286A1/es not_active IP Right Cessation
- 1996-07-17 CO CO96037512A patent/CO4700441A1/es unknown
- 1996-07-17 PE PE1996000541A patent/PE1698A1/es not_active IP Right Cessation
-
1998
- 1998-01-14 BG BG102188A patent/BG63631B1/bg unknown
- 1998-01-16 NO NO980209A patent/NO309322B1/no unknown
-
2000
- 2000-09-07 US US09/657,469 patent/US6274740B1/en not_active Expired - Lifetime
-
2001
- 2001-05-15 GR GR20010400710T patent/GR3035859T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24286A1 (es) | Nuevo proceso para la producción de una sal ácida calcica amorfa | |
| DE3768869D1 (de) | Verfahren und anlage zur herstellung eines eine stapelung von trockenen steinen nachahmenden bauelementes. | |
| DE69512942D1 (de) | Verfahren zur Herstellung von Silber-Palladium Pulver durch Aerosol Zersetzung | |
| DE69615413D1 (de) | Vorrichtung zum Entfernen keramischen Schalenformmaterials von Gussstücken durch alkalisches Spritzen | |
| DE60043983D1 (de) | Verfahren zur herstellung von phenylalkanen | |
| DE68920267D1 (de) | Verfahren zur Herstellung von einem durch Keramik verstärkten Verbundmaterial. | |
| DE69611751D1 (de) | Verfahren zur Herstellung von Zylinderblöcken | |
| BR9502907A (pt) | Processo para a extração de polissacarideos solúveis de material vegetal sólido | |
| DE69915403D1 (de) | Verfahren zur Herstellung von überbasischen Calciumsulfonat Detergentia | |
| IL149989A0 (en) | Method for decaying | |
| DE69722145D1 (de) | Verfahren zur Herstellung eines wärmeleitenden Materials | |
| DE60017108D1 (de) | Lösungsmittelextraktionsverfahren | |
| DE69710803D1 (de) | Verfahren zur Herstellung von geschlossenen Vesikeln durch Rehydratisierung von dehydratisierten Vesikeln | |
| ES2063974T3 (es) | Una nueva forma estable de cefradina, un proceso para su produccion y compuestos intermedios usados en tal proceso. | |
| BR0017236A (pt) | Processo para remoção de contaminantes de flocos de rpet | |
| DE69016838D1 (de) | Verfahren zur Herstellung von organischen Estern. | |
| ES2142253B1 (es) | Procedimiento para la preparacion de un producto carnico, torre de prensado y equipo para la realizacion de dicho procedimiento. | |
| BR9709264A (pt) | Processo para produzir e composto | |
| MX9302153A (es) | Proceso de secado por aspersion de la aminoguanidina. | |
| TW200502255A (en) | New method to produce a solid form of heparin | |
| TW375627B (en) | Process for removing dioxane from vapor phase mixtures of dioxane and water and the apparatus and process for minimizing or eliminating overflow of condensate | |
| ATE358119T1 (de) | Verfahren zur entfernung von spurlösungsmittel von einem hygroskopischen material | |
| AR025740A1 (es) | Procedimiento para la identificacion de al menos una sustancia quimica activa en una mezcla de substancias activas e inactivas con masas molares relativas de 150 a 30.000 | |
| BR8801016A (pt) | Processo para a remocao de materiais organicos | |
| DE69031880D1 (de) | Verfahren zur Herstellung eines halbleitenden kristallinen Filmes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20160717 |